DE60329839D1 - Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind - Google Patents

Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind

Info

Publication number
DE60329839D1
DE60329839D1 DE60329839T DE60329839T DE60329839D1 DE 60329839 D1 DE60329839 D1 DE 60329839D1 DE 60329839 T DE60329839 T DE 60329839T DE 60329839 T DE60329839 T DE 60329839T DE 60329839 D1 DE60329839 D1 DE 60329839D1
Authority
DE
Germany
Prior art keywords
reactive protein
prevention
treatment
tissue damage
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60329839T
Other languages
German (de)
English (en)
Inventor
Mark B Pepys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentraxin Therapeutics Ltd
Original Assignee
Pentraxin Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentraxin Therapeutics Ltd filed Critical Pentraxin Therapeutics Ltd
Application granted granted Critical
Publication of DE60329839D1 publication Critical patent/DE60329839D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE60329839T 2002-05-15 2003-05-14 Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind Expired - Lifetime DE60329839D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211136.7A GB0211136D0 (en) 2002-05-15 2002-05-15 Treatment and prevention of tissue damage
PCT/GB2003/002096 WO2003097104A1 (en) 2002-05-15 2003-05-14 Treatment and prevention of tissue damage

Publications (1)

Publication Number Publication Date
DE60329839D1 true DE60329839D1 (de) 2009-12-10

Family

ID=9936726

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60329839T Expired - Lifetime DE60329839D1 (de) 2002-05-15 2003-05-14 Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind

Country Status (11)

Country Link
US (1) US7615543B2 (enExample)
EP (1) EP1503800B1 (enExample)
JP (2) JP2005531559A (enExample)
AT (1) ATE446761T1 (enExample)
AU (1) AU2003234000B8 (enExample)
CA (1) CA2485852C (enExample)
DE (1) DE60329839D1 (enExample)
DK (1) DK1503800T3 (enExample)
ES (1) ES2333522T3 (enExample)
GB (1) GB0211136D0 (enExample)
WO (1) WO2003097104A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211136D0 (en) * 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
CN101845009B (zh) 2002-07-29 2012-10-03 卡达克斯药物公司 用于抑制和改善疾病的类胡萝卜素结构类似物
PT1596880E (pt) 2002-12-23 2011-06-06 Univ Rice William M Métodos e composições para suprimir a diferenciação de fibrócitos
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
GB0313386D0 (en) * 2003-06-10 2003-07-16 Univ London Treatment of disease
US20070265196A1 (en) * 2004-01-21 2007-11-15 Medvet Science Pty., Ltd. Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein
EP1582527A1 (en) * 2004-03-31 2005-10-05 Ciba SC Holding AG Synthesis of phosphorus based ligands
CA2654440C (en) * 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
ES2409756T3 (es) 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2405929B1 (en) 2009-03-11 2018-06-06 Promedior Inc. A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease
CA2754961C (en) 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
US8674027B2 (en) 2009-09-18 2014-03-18 Dow Global Technologies Llc Powdered thermoplastic polyolefin elastomer composition for slush molding processes
WO2011155956A1 (en) 2010-06-08 2011-12-15 Dow Global Technologies Llc Polyolefin elastomer composition for artificial leather applications
US20150087576A1 (en) * 2011-12-14 2015-03-26 The Texas A&M University System Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap)
EP2890300B1 (en) 2012-08-31 2019-01-02 Kenji Suzuki Supervised machine learning technique for reduction of radiation dose in computed tomography imaging
EP2957563A1 (en) * 2014-06-19 2015-12-23 Pentracor GmbH Separation material comprising phosphoryl choline derivatives
GB202002299D0 (en) * 2020-02-19 2020-04-01 Pentraxin Therapeutics Ltd Agents for use in the treatment of tissue damage
WO2021197371A1 (zh) * 2020-03-31 2021-10-07 南京金斯瑞生物科技有限公司 一种含有刚性连接子的生物偶联物
WO2022178594A1 (en) * 2021-02-25 2022-09-01 Baker Heart and Diabetes Institute C-reactive protein inhibitors
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage
KR20230060368A (ko) * 2021-10-27 2023-05-04 솔브레인 주식회사 환형 포스핀 화합물의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640913A (en) 1983-01-10 1987-02-03 American Cyanamid Company Phosphocholine derivatives having antihypertensive action
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US5811568A (en) 1992-10-08 1998-09-22 Shaman Pharmaceuticals, Inc. Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity
US5681829A (en) 1992-10-08 1997-10-28 Shaman Pharmaceuticals, Inc. Class of phosphocholine derivatives having antifungal activity
JP4524846B2 (ja) 2000-04-20 2010-08-18 日油株式会社 化粧料
US6764826B2 (en) 2000-06-08 2004-07-20 Board Of Regents, The University Of Texas System Inhibitors of C-reactive protein induced inflammation
US7390795B2 (en) * 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
JP4472333B2 (ja) 2001-08-08 2010-06-02 ペントラキシン セラピューティクス リミテッド 好ましくないタンパク質群を患者の血漿から除去するための薬剤
GB0211136D0 (en) * 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage

Also Published As

Publication number Publication date
JP2010174013A (ja) 2010-08-12
CA2485852A1 (en) 2003-11-27
ATE446761T1 (de) 2009-11-15
GB0211136D0 (en) 2002-06-26
ES2333522T3 (es) 2010-02-23
DK1503800T3 (da) 2010-02-01
AU2003234000B8 (en) 2008-07-31
AU2003234000A1 (en) 2003-12-02
US7615543B2 (en) 2009-11-10
JP2005531559A (ja) 2005-10-20
WO2003097104A1 (en) 2003-11-27
EP1503800A1 (en) 2005-02-09
AU2003234000B2 (en) 2008-06-05
CA2485852C (en) 2012-01-17
EP1503800B1 (en) 2009-10-28
US20060019930A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
ATE446761T1 (de) Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind
IL311603B1 (en) Bispecific antibodies and compounds containing them for cancer treatment
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
DE69942578D1 (de) Bifunktionelle moleküle sowie darauf basierende therapien.
CY1124232T1 (el) Συνδετικα μορια συνδεσης pd-l1 και lag-3
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
EA200301117A1 (ru) Антитела против vla-1
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
DK3085783T3 (da) Bispecifikt antistof som substitution for funktionelle proteiner
EA200801521A1 (ru) Лиганды, которые обладают специфичностью связывания к vegf и/или egfr, и способы их применения
WO2006020060A3 (en) Iap binding compounds
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
EA201001734A1 (ru) Улучшенные связывающие молекулы на основе фибронектина и их применение
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
BRPI0518701B8 (pt) Processos para a preparação de um sistema catalisador e para a polimerização de olefinas
ATE40555T1 (de) Verfahren zur organischen synthese von oligosacchariden,welche galactosamin- und uronsaeure-motive umfassen, oligosaccharide und ihre biologischen verwendungen.
DE69942565D1 (de) Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
ATE414718T1 (de) Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
WO2003071269A3 (en) Methods and apparatuses for characterizing stability of biological molecules
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
EP2335737A3 (en) Artificial platelets
WO2006129843A3 (en) Bispecific capturing molecule
WO2004069860A3 (en) Isg15-conjugated proteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition